A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

Active:	No
Cancer Type:	Breast Cancer Unknown Primary	NCT ID:	NCT04647487
Trial Phases:	Phase I	Protocol IDs:	17575 (primary) NCI-2021-00207 J2J-MC-JZLB 2020-002810-42
Eligibility:	18 Years and older, Female	Study Type:	Basic Science
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT04647487

Summary

The purpose for this study is to see if the study drug, LY3484356, is safe and to
determine what effects it has on breast cancer in participants with Estrogen Receptor
Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given
prior to surgery. Participation in this study could last up to 2.5 months.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.